Lorus Therapeutics Inc.
Records under this name other than patents Lorus Therapeutics Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Lorus Therapeutics Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,309,247 | 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,080,739 | Aryl Imidazoles and Their Use as Anti-Cancer Agents Formerly held Term ended Term ended Aug 9, 2025 · High confidence | Term ended | Term ended Aug 9, 2025 | High confidence |
| US 8,148,392 | 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer Formerly held Lapsed on the fee record Ended Apr 3, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 3, 2024 | From the USPTO record |
| US 8,394,815 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Formerly held Term ended Ended no later than Aug 19, 2023 · From the USPTO record | Term ended | Ended no later than Aug 19, 2023 | From the USPTO record |
| US 8,987,305 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Formerly held Lapsed on the fee record Ended Mar 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Mar 24, 2023 | From the USPTO record |
| US 8,969,372 | Aryl imidazoles and their use as anti-cancer agents Formerly held Lapsed on the fee record Ended Mar 3, 2023 · Medium confidence | Lapsed on the fee record | Ended Mar 3, 2023 | Medium confidence |
| US 7,884,120 | 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Formerly held Lapsed on the fee record Ended Feb 8, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 8, 2023 | From the USPTO record |
| US 8,287,851 | Use of interleukin 17E for the treatment of cancer Formerly held Lapsed on the fee record Ended Oct 16, 2016 · From the USPTO record | Lapsed on the fee record | Ended Oct 16, 2016 | From the USPTO record |
| US 7,405,205 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase Formerly held Lapsed on the fee record Ended Jul 29, 2016 · From the USPTO record | Lapsed on the fee record | Ended Jul 29, 2016 | From the USPTO record |
| US 6,280,774 | Immunomodulating compositions from bile Formerly held Term ended Term ended May 16, 2016 · From the USPTO record | Term ended | Term ended May 16, 2016 | From the USPTO record |